User login
Patients with glioblastoma and other high-grade gliomas have poor outcomes and are challenging to treat. The relative rarity of these tumors has made large-scale, practice-changing trials difficult to accomplish and has led to the formation of large multinational organizations that focus on neuro-oncology. This has resulted in the rapid completion of several large trials that in some cases have set new standards of care that can offer increased progression-free and overall survivals for some patients. The incorporation of correlative tissue studies in these trials has led to the identification of prognostic and predictive genetic markers that demonstrate the heterogeneity of these tumors and will assist in developing individualized treatment strategies as research continues to uncover new therapeutic targets. This review of recently completed and in-progress phase 3 trials in high-grade gliomas highlights the developments and future directions in the treatment of these tumors...
*For PDFs of the full article and related Commentary, click on the links to the left of this introduction.
Patients with glioblastoma and other high-grade gliomas have poor outcomes and are challenging to treat. The relative rarity of these tumors has made large-scale, practice-changing trials difficult to accomplish and has led to the formation of large multinational organizations that focus on neuro-oncology. This has resulted in the rapid completion of several large trials that in some cases have set new standards of care that can offer increased progression-free and overall survivals for some patients. The incorporation of correlative tissue studies in these trials has led to the identification of prognostic and predictive genetic markers that demonstrate the heterogeneity of these tumors and will assist in developing individualized treatment strategies as research continues to uncover new therapeutic targets. This review of recently completed and in-progress phase 3 trials in high-grade gliomas highlights the developments and future directions in the treatment of these tumors...
*For PDFs of the full article and related Commentary, click on the links to the left of this introduction.
Patients with glioblastoma and other high-grade gliomas have poor outcomes and are challenging to treat. The relative rarity of these tumors has made large-scale, practice-changing trials difficult to accomplish and has led to the formation of large multinational organizations that focus on neuro-oncology. This has resulted in the rapid completion of several large trials that in some cases have set new standards of care that can offer increased progression-free and overall survivals for some patients. The incorporation of correlative tissue studies in these trials has led to the identification of prognostic and predictive genetic markers that demonstrate the heterogeneity of these tumors and will assist in developing individualized treatment strategies as research continues to uncover new therapeutic targets. This review of recently completed and in-progress phase 3 trials in high-grade gliomas highlights the developments and future directions in the treatment of these tumors...
*For PDFs of the full article and related Commentary, click on the links to the left of this introduction.